Begin main content

Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety

Published on: January 2, 2015
Project Number: RB0776-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness and safety of telaprevir, boceprevir, simeprevir or sofosbuvir and peginterferon + ribavirin (PR) combination treatments in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior direct acting antiviral (DAA) plus (PR) therapy or PR therapy alone?

Key Message

Four relevant conference abstracts of randomized controlled trials were identified regarding the clinical effectiveness and safety of triple therapy in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior direct acting antiviral (DAA) plus (PR) therapy or PR therapy alone.

Tags

ribavirin, antiviral agents, hepatitis c, infectious diseases, telaprevir, boceprevir, simeprevir, sofosbuvir, peginterferon